Aimovig serving as a miracle drug for chronic migraine – A clinical Review

Registration ID: IJNRD_184214

Published ID: IJNRD2211257

DOI: Click Here to Get

MARY MANISHA MANNAM , Dr. Sneha Thakur , Uma Rani Yadagiri

Aimovig, calcitonin gene related peptide receptor, headache, Migraine.

Migraine being a very serious issue unaddressed by most of the patient assuming it as a normal headache is leading to the chronic conditions of the individual. These conditions are increasing across the globe and the awareness within our communities need to be taken care of as it is a complex neurological disorder which is related to several CNS systems such as sensorics and motoric, cognitive, affective and autonomous systems is categorised as migraine. The calcitonin gene related peptide receptor (CGRP) is the receptor of calcitonin family which also includes amylin, adrenomedullin and calcitonin receptors. Among these CGRP receptors play a major role in migraine but its exact role is yet to be analysed. Already existing treatments such as Triptans showed high agonist activity at serotonin receptors but not every triptan has the affinity at the receptors. However, Patients mentioned that the response of the body towards this triptans is poor and others may have headache recurrence and chest syndromes. Aimovig a miracle drug came to existence showing its effectiveness more appropriately and significantly by pre-clinical and clinical studies proving to show the statistical analysis of 70mg of aimovig shows p value of <0.001 and of 140mg p value of <0.001 which are similar. The secondary outcomes of the results are the % of participants with at least 50% of reduction in monthly migraine days (which differ from each patient). Aimovig is proving to show less adverse events associated irrespective of the other factors and showed more effectiveness in reducing the migraine condition and improving the quality of life of the patients.

Published Paper   E-Certificate

MARY MANISHA MANNAM, Dr. Sneha Thakur, & Uma Rani Yadagiri (November-2022). Aimovig serving as a miracle drug for chronic migraine – A clinical Review. INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT, 7(11), c450-c456. https://ijnrd.org/papers/IJNRD2211257.pdf

Volume 7 Issue 11, November-2022

Pages : c450-c456

Paper Reg. ID: IJNRD_184214

Published Paper Id: IJNRD2211257

Downloads: 000121976

Research Area: Pharmacy

Country: RANGA REDDY , TELANGANA, INDIA

Published Paper PDF: https://ijnrd.org/papers/IJNRD2211257.pdf

Published Paper URL: https://ijnrd.org/viewpaperforall?paper=IJNRD2211257

Journal Name: INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT(IJNRD)

ISSN: 2456-4184 | IMPACT FACTOR: 8.76 Calculated By Google Scholar | ESTD YEAR: 2016

An International Scholarly Open Access Journal, Peer-Reviewed, Refereed Journal Impact Factor 8.76 Calculate by Google Scholar and Semantic Scholar | AI-Powered Research Tool, Multidisciplinary, Monthly, Multilanguage Journal Indexing in All Major Database & Metadata, Citation Generator

Publisher: IJNRD (IJ Publication) Janvi Wave | IJNRD.ORG | IJNRD.COM | IJPUB.ORG

This work is licensed under a Creative Commons Attribution 4.0 International License and The Open Definition

Call For Paper - Volume 10 | Issue 10 | October 2025

IJNRD is a Scholarly Open Access, Peer-reviewed, and Refereed Journal with a High Impact Factor of 8.76 (calculated by Google Scholar & Semantic Scholar | AI-Powered Research Tool). It is a Multidisciplinary, Monthly, Low-Cost Journal that follows UGC CARE 2025 Peer-Reviewed Journal Policy norms, Scopus journal standards, and Transparent Peer Review practices to ensure quality and credibility. IJNRD provides indexing in all major databases & metadata repositories, a citation generator, and Digital Object Identifier (DOI) for every published article with full open-access visibility.

The INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT (IJNRD) aims to advance applied, theoretical, and experimental research across diverse fields. Its goal is to promote global scientific information exchange among researchers, developers, engineers, academicians, and practitioners. IJNRD serves as a platform where educators and professionals can share research evidence, models of best practice, and innovative ideas, contributing to academic growth and industry relevance.

Indexing Coverage includes Google Scholar, SSRN, ResearcherID-Publons, Semantic Scholar (AI-Powered Research Tool), Microsoft Academic, Academia.edu, arXiv.org, ResearchGate, CiteSeerX, ResearcherID (Thomson Reuters), Mendeley, DocStoc, ISSUU, Scribd, and many more recognized academic repositories.

How to submit the paper?

By Our website

Click Here to Submit Paper Online

By Mail

Send your paper to editor@ijnrd.org

Important Dates for Current issue

Paper Submission Open For: October 2025

Current Issue: Volume 10 | Issue 10 | October 2025

Impact Factor: 8.76

Last Date for Paper Submission: Till 31-Oct-2025

Notification of Review Result: Within 1-2 Days after Submitting paper.

Publication of Paper: Within 01-02 Days after Submititng documents.

Frequency: Monthly (12 issue Annually).

Journal Type: IJNRD is an International Peer-reviewed, Refereed, and Open Access Journal with Transparent Peer Review as per the new UGC CARE 2025 guidelines, offering low-cost multidisciplinary publication with Crossref DOI and global indexing.

Subject Category: Research Area

Call for Paper: More Details